Biotechnology
Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery
Collaboration to develop 3D in vitro models of the brain for the discovery of
therapeutic candidates using Inventia's novel 3D cell culture platform, RASTRUM™
SYDNEY, Feb. 15, 2023 /PRNewswire/ -- February 16, 2023, Inventia Life Science
2023-02-16 06:00
2254
Tetracore Announces USDA Purchase of ASF and FMD Diagnostic Test Kits
ROCKVILLE, Md., Feb. 16, 2023 /PRNewswire/ -- Tetracore, Inc. (Tetracore®) is pleased to announce its partnership with the United States Department of Agriculture's (USDA) Animal and Plant Health Inspection Service (APHIS) to provide a stock of PCR kits for both African Swine Fever (ASF) and Foo...
2023-02-16 04:35
2748
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
Randomized, double-blind, placebo-controlled study to evaluate efficacy of novel pan-GI prokinetic in patients with gastroparesis ROSCREA, Ireland and FREIBURG, Germany, Feb. 15, 2023 /PRNewswire/ -- Renexxion Ireland Limited, a private biopharmaceutical company committed to delivering innovativ...
2023-02-15 21:30
2591
AnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services Provider
NEW YORK, Feb. 15, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States andChina focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platfo...
2023-02-15 21:00
3204
Henlius Announces U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02
* The first Chinese biosimilar approved in both China and the EU, and potentially to be approved in the U.S. - * HLX02 (trastuzumab for injection, trade name in China: HANQUYOU; trade name inEurope: Zercepac®; trade names in Australia: Tuzucip® and Trastucip®) has been approved in more than 3...
2023-02-15 16:49
2736
GILEAD TO PRESENT DATA AT APASL 2023 ON EFFECTIVE MODELS FOR MONITORING AND TREATING HEPATITIS C AND EFFICACY OF ANTIVIRAL TREATMENTS FOR HIV-1 AND HBV-COINFECTED ADULTS
- Study recommends a simplified strategy for baseline testing and minimal monitoring for treatment of hepatitis C virus (HCV) infection with DAA Therapies - Review of implementation science projects toward HCV Elimination by 2030 in Asia proved effective in improving patient outcomes - Efficacy ...
2023-02-15 10:00
2343
Innovent Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy
ROCKVILLE, Md. and SUZHOU, China, Feb. 15, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2023-02-15 08:00
3476
Telix Collaboration on Next Generation Urologic-Oncology Theranostic Published in Journal of Nuclear Medicine
MELBOURNE, Australia, Feb. 15, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the successful completion of its joint research project conducted with Heidelberg University Hospital (UKHD) under the Research Cooperation Agreement announced inFebrua...
2023-02-15 04:51
1808
Eluminex Biosciences Announces Completion of Initial Enrollment in Part A of the CLARITY Study Evaluating a Human Recombinant Collagen-derived (rhCIII) Biosynthetic Cornea (EB-301)
Initial Part A results to be presented at the upcoming American Society of Cataract and Refractive Surgery Annual Meeting EB-301 has the potential to be the world's first approved rhCIII biosynthetic corneal implant for the treatment of corneal blindness SUZHOU, China and SAN FRANCISCO, Feb. 14,...
2023-02-15 01:00
1669
Eurofins Discovery Collaborating with Invasight on Cancer Therapies
SAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Eurofins Discovery, the leading provider of products and services to the drug discovery industry, today announced its collaboration withInvasight, a Switzerland-based biotech developing cancer therapies. The collaboration focuses on advancing first-in-cla...
2023-02-15 00:10
1996
CJ Biomaterials Teams with Banila Co. to Develop New 100% Biobased Cosmetic Jar using Amorphous PHA
WOBURN, Mass., Feb. 14, 2023 /PRNewswire/ -- CJ Biomaterials, Inc., a division ofSouth Korea-based CJ CheilJedang and a primary producer of polyhydroxyalkanoates (PHAs), has produced the first cosmetic jar based on their amorphous PHA technology, under the tradename, PHACT™. The cosmetic jar was...
2023-02-14 22:00
2125
U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
* Modified agreement also includes the development of an updated vaccine in fall 2023 GAITHERSBURG, Md., Feb. 13, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, toda...
2023-02-13 21:00
2733
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
Approval follows U.S. FDA clearance of IND application for BCMA/CD19 dual-targeting FasTCAR-T GC012F Company plans to initiate Phase 1/2 clinical trial in China in third quarter of 2023 SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Feb. 13, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ...
2023-02-13 20:30
1930
Vmade Launched Cooperation with Fulgent Life to Build a Cross-Border SaaS and Payment Integration Solution for Private Growth
BEIJING, Feb. 13, 2023 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the
"Company") (NASDAQ: WETG
2023-02-13 20:00
2132
Concept Medical granted Investigational Device Exemption (IDE) approval for their Magic Touch Sirolimus Coated Balloon for the treatment of Below the Knee (BTK) Arterial Disease
TAMPA, Fla., Feb. 13, 2023 /PRNewswire/ -- Concept Medical Inc.
2023-02-13 14:53
1959
Boan Biotech's Investigational Anti-CD25 Antibody BA1106 Administered for First Patient in Phase I Clinical Trial
YANTAI, China, Feb. 13, 2023 /PRNewswire/ -- Luye Pharma Group today announced that BA1106, an investigational non-IL-2 blocking anti-CD25 antibody developed by its subsidiary Boan Biotech, has been administered for the first patient in a Phase I clinical trial. This trial is designed to evaluate...
2023-02-13 08:39
2666
HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities
* HanAll will invest in Interon Laboratories, a preclinical-stage biotechnology company focused on treating complex neurological disorders * Interon is developing a new category of immunotherapy for people with neurological and immune disorders starting with autism spectrum disorder SEOUL, So...
2023-02-10 20:00
2794
Nona Biosciences Enters into HCAb Based Antibody Discovery Collaboration Agreement with Mythic Therapeutics
CAMBRIDGE, Mass., Feb. 10, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to cutting edge technology innovations, and providing a total solution from "Idea to IND" ("I to ITM"), today announced that it has entered into a collaboration agreement ...
2023-02-10 13:00
1717
AcuraBio expands cGMP plasmid DNA CDMO services with Cytiva's latest single-use purification technology to alleviate supply constraints for mRNA and cell & gene therapies
* AcuraBio selects Cytiva's latest two-step purification protocol to offer a productive plasmid DNA service to its customers globally to alleviate supply constraints for mRNA and cell & gene therapies * The latest purification technology will offer efficient processing time for plasmid DNA pr...
2023-02-10 09:34
6010
Technoderma Medicines Initiates TDM-180935 Atopic Dermatitis Clinical Program with Phase 1 Dose Escalation Trial
SAN DIEGO, Feb. 9, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing healthy volunteer subjects in its Phase 1 clinical trial of topical TDM-180935 ointment. This first clinical trial in ...
2023-02-09 21:00
1527
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 257 media titles]
2024-05-02 01:21
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 251 media titles]
2024-04-30 15:13Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2943
